# A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

> **NCT04437511** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 1736 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Donanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04437511
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-19
- **Primary completion:** 2023-04-14
- **Final completion:** 2028-11
- **Target enrollment:** 1736 (ACTUAL)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437511, "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04437511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*